Next-generation conjugates: small peptides to transform targeted cancer therapy

“Our mission is to extend the therapeutic index of toxic payloads that effectively target cancer.”Lauren Coyle, Launch Commissioning Editor, Bioconjugation Insights, speaks with Michelle Morrow, Chief Scientific Officer, Avacta, about a novel drug delivery platform that utilizes a small peptide with a capping group conjugated to a cytotoxic cancer drug. She discusses the advantages of the platform over traditional ADC therapies including the improved precision and safety of cancer treatment.Bioconjugation Insights is the only dedicated provider of specialized, high-quality, Open Access digital content tailored to the bioconjugation field. To read more of our Open Access content, please register here.